We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Permanent Contraception by the Obstruction of Fallopian Tubes

By HospiMedica International staff writers
Posted on 03 Feb 2009
A permanent contraception and sterilization system provides a minimally invasive, nonincisional alternative to bilateral tubal ligation, the traditional means of female sterilization. More...


The Adiana permanent contraception system enables a novel, two-step approach to permanent female sterilization. First, a catheter is positioned immediately inside the opening of the patient's fallopian tube using a hysteroscope, eliminating the need for any incisions. The catheter applies a very low level of bipolar radiofrequency (RF) energy to remove a thin layer of the cells lining a one-centimeter section of the interior of the fallopian tube. The catheter then delivers a soft polymer implant, smaller than a grain of rice, called a "matrix,” which remains within the prepared section of the fallopian tube. The procedure is then repeated on the other fallopian tube. The procedure is designed so that healthy tissue will grow into the matrix to create a complete blockage of each tube. A confirmatory dye test called a hysterosalpingogram (HSG) is conducted at three months post-procedure to ensure the fallopian tubes are completely blocked and that the woman can begin relying on the Adiana matrix for permanent contraception. The procedure generally requires only local anesthesia, and can be performed in a physician's office; patients are normally able to return to work or resume their everyday activities within a day. The Adiana permanent contraception system is a product of Hologic (Bedford, MA, USA), and it has received the European Community (CE) marking and approval by the U.S. Food and Drug Administration (FDA).

"Hysteroscopic sterilization gives women another choice in permanent sterilization,” said Andrew Baxter, M.D., a consultant and honorary senior lecturer in the department of obstetrics and gynecology at the Royal Hallamshire Hospital (Sheffield, UK). "It also allows them to avoid hospital admission, anesthetic and the discomfort and risks attached to laparoscopy.”

A hysteroscope is in fact a modification of a traditional resectoscope, used for transurethral resection of the prostate. It has a double-channeled sheath allowing for continuous flow of fluid or gas media into the uterus through the larger channel, while allowing for a smaller outflow through the smaller channel. This results in the distention of the uterine cavity. After cervical dilation, an operative hysteroscope with a channel to allow specialized instruments to enter the cavity is used to perform the surgery. Other typical procedures include endometrial ablation, submucosal fibroid resection, and endometrial polypectomy.

Related Links:

Hologic
Royal Hallamshire Hospital


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.